


Cite this: *RSC Adv.*, 2025, 15, 12331

High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs)[†]

Phongthon Kanjanasirirat,^{abc} Kedchin Jearawuttanakul,^c Sawinee Seemakhan,^c Suparek Borwornpinyo,^{cd} Patompon Wongtrakongate,^{ef} Suradej Hongeng^{cg} and Sitthivut Charoensutthivarakul^{id*acf}

Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and aggressive tumor of the primary central nervous system primarily affecting children. It typically originates in the cerebellum and brain stem and is associated with a low survival rate. While standard chemotherapy has been used as a primary treatment for AT/RTs, its success rate is unsatisfactory, and patients often experience severe side effects. Therefore, there is an urgent need to develop new and effective treatment strategies. One promising approach for identifying new therapies is drug repurposing. Although many FDA-approved drugs have been repurposed for various cancers, there have been no reports of such applications for AT/RTs. In this study, a library of 2130 FDA-approved drugs was screened using a high-throughput screening system against 2D traditional cultures and 3D spheroid cultures of AT/RT cell lines (BT-12 and BT-16). From this screening, colchicine, a non-chemotherapeutic agent, was identified as a promising candidate. It exhibited IC₅₀ values of 0.016 and 0.056 μ M against 2D BT-12 and 2D BT-16 cells, respectively, and IC₅₀ values of 0.004 and 0.023 μ M against 3D BT-12 and BT-16 spheroid cultures. Additionally, the cytotoxic effects of colchicine on human brain endothelial cells and human astrocytes were evaluated, and CC₅₀ > 20 μ M was observed, which is over two orders of magnitude higher than its effective concentrations in AT/RT cells, indicating considerably lower toxicity to normal brain cells and brain endothelial cells. In conclusion, colchicine shows significant potential to be repurposed as a treatment for AT/RTs, providing a safer and more effective therapeutic option for this rare and challenging disease.

Received 24th February 2025
Accepted 3rd April 2025

DOI: 10.1039/d5ra01341k

rsc.li/rsc-advances

Introduction

Atypical teratoid/rhabdoid tumor (AT/RT) is a rare central nervous system (CNS) tumor that primarily affects children, particularly

those under the age of 3 years. This type of tumor is classified as an atypical teratoid tumor due to its teratoid malignant properties, which arise from the abnormal development of pluripotent cells, such as germ cells and embryonal cells.¹ Moreover, AT/RTs exhibit a prominent feature of rhabdoid morphology, characterized by sheets and clusters of large epithelioid cells with vesicular paranuclear inclusions and associated with a high tumor grade.² These characteristics give the tumor its name, atypical teratoid/rhabdoid tumor (AT/RT).¹ The primary cause of AT/RTs is the deletion of chromosome 22 at the Chr22q11.2 region, which contains the *SMARCB1* tumor suppressor gene.³

AT/RTs typically develop in two major areas of the brain: the cerebellum and brain stem.⁴ The cerebellum, located at the base of the brain, has a functional role in controlling movement, balance, and posture, while the brain stem controls breathing, heart rate, and muscle activities involved in seeing, hearing, walking, talking, and eating.⁵ Therefore, symptoms of AT/RTs often include nausea, vomiting, morning headache, drowsiness, and a loss of balance and movement such as eye or facial muscle weakness.⁶

^aSchool of Bioinnovation and Bio-based Product Intelligence, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand. E-mail: sitthivut.cha@mahidol.ac.th; Tel: +66-2-201-5899

^bDepartment of Pathobiology, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand

^cExcellent Center for Drug Discovery (ECDD), Faculty of Science, Mahidol University, Bangkok, 10400, Thailand

^dDepartment of Biotechnology, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand

^eDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand

^fCenter for Neuroscience, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand

^gDepartment of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand

[†] Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5ra01341k>



Due to its rarity, the incidence of AT/RTs is often underestimated. The overall incidence rate is approximately 0.07 per 1 00 000, with the highest incidence rate (0.54 per 1 00 000) occurring in children under 1 year of age and the lowest rate (0.01 per 1 00 000) in individuals aged 6–19 years.⁷ Despite its rarity, AT/RTs have a poor prognosis, with a global 4-year survival rate of just 43%.⁸ Currently, there is no well-defined gold standard treatment for AT/RTs. Chemotherapy is the primary treatment option, involving drugs such as vincristine, methotrexate, etoposide, cyclophosphamide, cisplatin, and doxorubicin.^{9–11} However, these drugs cause severe side effects including hair loss, diarrhea, nausea and vomiting, weakness, cardiac dysfunction, and abnormal neurological development.¹² For this reason, there is an urgent need for new and more effective therapies.

Drug repurposing has emerged as a promising and effective approach to identify new therapeutic agents. FDA-approved drugs are suitable for repurposing due to their safety profiles.^{13,14} Several FDA-approved drugs have already been repurposed for anticancer activity.¹³ For example, itraconazole, an antifungal drug, has shown strong anticancer activities in lung and prostate cancers^{15,16} by inhibiting mTOR activity and VEGFR2 glycosylation, which reduces angiogenesis.^{17,18} Nelfinavir, an anti-HIV drug, has demonstrated activity against pancreatic cancer by targeting the PI3K/AKT signaling pathway.¹⁹ However, the repurposing of FDA-approved drugs for AT/RTs has not been previously reported.

The *in vitro* screening of anticancer compounds has progressed beyond traditional 2D cell culture to include 3D

spheroid culture. This approach has become increasingly prevalent in cancer research, including breast,²⁰ cervical,²⁰ colon,²¹ lung,²² pancreatic,^{23,24} and prostate cancers,^{25–27} among others. Compared to 2D models, 3D spheroids better mimic several features of solid tumors, such as their structural organization, biological responses, release of signaling molecules, gene expression patterns, and drug resistance. These distinctive and unique properties make 3D cell aggregates highly valuable as *in vitro* models for testing new anticancer therapies.²⁸ Like solid tumors, the internal structure of spheroids consists of distinct cell layers.^{29,30} These include the proliferative zone in the outer layer, the quiescent zone in the middle layer, and the necrotic zone in the inner core.³¹ The layered structure of spheroids is a key factor in reducing the effectiveness of anti-cancer drugs and drug-loaded nanocarriers, as the deeper layers are less accessible to therapeutic agents. Therefore, the inclusion of 3D spheroid culture in anticancer research is a crucial step forward in developing new treatments.

The objective of this study is to identify an FDA-approved, non-chemotherapeutic drug that can effectively treat AT/RT tumor cells. To achieve this, an in-house library of 2130 FDA-approved drugs was screened using a high-throughput screening system against traditional 2D and 3D spheroid cultures of AT/RT cell lines. The cell lines used in this study, BT-12 and BT-16, are SMARCB1-deficient epithelial AT/RT cells generously provided by Dr Peter Houghton from St. Jude Children's Research Hospital.³² Although both cell lines originate from the same type of pediatric brain tumor, they exhibit different levels of chemosensitivity. BT-12 cells are more




Fig. 1 High-throughput screening of 2130 FDA-approved drugs against AT/RT cells. The primary screening was conducted in BT-12 cells (A) and BT-16 cells (B) using FDA-approved drugs at a concentration of 10 μ M. Hit compounds were identified based on their ability to inhibit cancer cell viability by over 80% indicated by the orange dotted line. A total of 104 hit compounds were effective against BT-12 cells and BT-16 cells as shown in (C). Amongst these, 62 compounds were classified as chemotherapeutic drugs (orange dots), while 42 compounds were identified as non-chemotherapeutic drugs (blue dots) (C). Doxorubicin served as the positive control (red dot), and DMSO served as the negative control (green dot).



responsive to chemotherapeutic drugs, such as vincristine, cisplatin, doxorubicin, and etoposide, while BT-16 cells exhibit a higher level of resistance to these treatments.^{33,34} These differences in chemosensitivity make the two cell lines valuable for identifying effective FDA-approved drugs and obtaining significant data for potential therapies.

Results

Forty-two non-chemotherapeutic drugs identified as effective against AT/RT cells

Many FDA-approved drugs have been successfully repurposed for various types of anticancer activities. However, there has been no report on repurposing FDA-approved drugs specifically for AT/RTs. In this study, a library of 2130 FDA-approved drugs was screened against AT/RT cells. The initial single-concentration screening identified 117 and 169 out of 2130 compounds that inhibited the viability of BT-12 and BT-16 cells by more than 80%, respectively (Fig. 1A and B). When the

effective compounds for both cell lines were merged, 104 hit compounds were identified (Fig. 1C and Table S1†). These 104 hit compounds were further classified into non-chemotherapeutic drugs and chemotherapeutic drugs. Amongst them, 42 compounds were identified as non-chemotherapeutic agents. These non-chemotherapeutic agents underwent secondary screening, including dose-dependent testing, to determine their IC₅₀ values.

Analysis of the dose-response relationship of three selected FDA-approved drugs

From the primary screening, 42 non-chemotherapeutic drugs (Fig. 1C, blue dot) were investigated for their potential to act as anti-AT/RT agents. These compounds were assayed in a dose-dependent manner on BT-12 and BT-16 cells. Amongst them, three FDA-approved drugs, colchicine, digoxin, and emetine, exhibited significant effects on AT/RT cell viability, with IC₅₀ values below 0.1 μM for both cell lines (Fig. 2A and B). Colchicine, an anti-inflammatory drug, was effective with IC₅₀ values




Fig. 2 Dose-response effects of three FDA-approved drug candidates on AT/RT cells. (A) IC₅₀ comparison graph between BT-12 cells and BT-16 cells highlighting the three drug candidates in orange dots. (B) IC₅₀ values of three FDA-approved drugs affect AT/RT cell viability corresponding to the numbered orange dots in (A). (C–F) Dose-dependent effects on BT-12 cell viability for colchicine (C), digoxin (D), emetine (E), with doxorubicin as a control (F). (G–J) Dose-dependent effects on BT-16 cell viability for colchicine (G), digoxin (H), emetine (I), and doxorubicin (J).






Fig. 3 Cytotoxicity testing (CC_{50}) of the hit compounds against the normal cells. (A–D) Dose-dependent cytotoxicity effects of colchicine (A), digoxin (B), emetine (C), and doxorubicin (D) on the viability of human cerebral microvascular endothelial cells (hCMEC/D3 cells). (E–H) Dose-dependent cytotoxicity effects of colchicine (E), digoxin (F), emetine (G), and doxorubicin (H) on the viability of primary astrocytes.

of 0.016 and 0.056 mM for BT-12 and BT-16 cells, respectively (Fig. 2B, C, and G). Meanwhile, digoxin, a cardiovascular drug, inhibited the proliferation of BT-12 and BT-16 cells at IC_{50} values of 0.080 and 0.076 mM, respectively (Fig. 2B, D, and H). Emetine, an antiprotozoal drug, also showed potential effects on BT-12 and BT-16 cells at IC_{50} values of 0.090 and 0.093 mM, respectively (Fig. 2B, E, and I). These findings suggested that colchicine, digoxin, and emetine have strong potential as anti-AT/RT agents.

Colchicine demonstrates anti-AT/RT activity without cytotoxicity in brain endothelial and brain normal cells

The IC_{50} values of the hit compounds—colchicine, digoxin, and emetine—are critical to evaluating their potential as anti-AT/RT agents. However, assessing the CC_{50} of these compounds in normal cells is equally important to determine their therapeutic windows using the selectivity index (SI) criterion. The SI is calculated as the ratio of a compound's toxic concentration (CC_{50}) to its effective bioactive concentration (IC_{50}). Thus, cytotoxicity testing of these hit compounds in normal cells is essential to assess their safety profile. In this study, the concentration of colchicine that inhibits 50% of normal cell viability (CC_{50}) was found to exceed 20 μM in human cerebral

microvascular endothelial cells (hCMEC/D3 cells) and human normal brain cells (astrocytes). This CC_{50} value is over two orders of magnitude higher than its effective concentrations (IC_{50}) against AT/RT cells, making it safer compared to other hit compounds (Fig. 3). These findings suggest that colchicine is relatively safe for normal brain cells and brain endothelial cells, which are likely to encounter the drug before its penetration into the brain.

The SI values of the hit compounds were evaluated and are presented in Table 1 for hCMEC/D3 cells and Table 2 for astrocytes. The analysis revealed that colchicine exhibited SI values exceeding 100 for both cell types, indicating a relatively large therapeutic window. By contrast, the SI values for digoxin and emetine were less than 100, which aligns with the SI values observed for the chemotherapeutic drug doxorubicin. These findings highlight colchicine as a safe candidate for further research in the treatment of AT/RTs.

Colchicine inhibits cell growth in three-dimensional (3D) AT/RT spheroid models

In addition to its effects in 2D conventional cancer cell cultures, the effects of colchicine were also evaluated in 3D cancer spheroid models, which better mimic the behavior of cancer

Table 1 Selectivity index (SI) of hit compounds in human cerebral microvascular endothelial cells (hCMEC/D3)

No.	FDA-approved drugs	BT-12 cells (IC_{50} : μM)	BT-16 cells (IC_{50} : μM)	hCMEC/D3 cells (CC_{50} : μM)	SI (CC_{50}/IC_{50})	
					hCMEC/D3: BT-12	hCMEC/D3: BT-16
1	Colchicine	0.016	0.056	>20	>1250	>357.143
2	Digoxin	0.080	0.076	0.101	1.263	1.329
3	Emetine	0.090	0.093	2.697	29.267	29
4	Doxorubicin	0.028	0.042	0.699	24.964	16.64



Table 2 Selectivity index (SI) of hit compounds in primary astrocytes

No.	FDA-approved drugs	BT-12 cells (IC ₅₀ : μ M)	BT-16 cells (IC ₅₀ : μ M)	Astrocytes (CC ₅₀ : μ M)	SI (CC ₅₀ /IC ₅₀)	
					Astrocytes: BT-12	Astrocytes: BT-16
1	Colchicine	0.016	0.056	>20	>1250	>357.143
2	Digoxin	0.080	0.076	0.102	1.275	1.342
3	Emetine	0.090	0.093	1.238	13.756	13.312
4	Doxorubicin	0.028	0.042	0.131	4.679	3.119




Fig. 4 Effect of colchicine on three-dimensional (3D) AT/RT spheroid growth models. BT-12 spheroids were treated with colchicine (A) or doxorubicin (B) at varying concentrations. The percentage effect of colchicine (red line) and doxorubicin (dark line) on BT-12 spheroid viability is shown in (C). Similarly, BT-16 spheroids were exposed to colchicine (D) or doxorubicin (E) at the stated concentrations. The percentage effect of colchicine (red line) and doxorubicin (black line) on BT-16 spheroid viability is presented in (F). Hoechst (green) and ethidium homodimer (orange) staining were used to distinguish live line and dead cells, respectively.

cells in the human body. The results of this study found that colchicine effectively inhibited the viability of 3D AT/RT spheroids at nanomolar concentrations. Colchicine demonstrated EC_{50} values of 14 and 37 nM for BT-12 and BT-16 spheroids, respectively (Fig. 4). Additionally, the EC_{50} value of colchicine in the BT-12 spheroid showed greater efficacy compared to doxorubicin (Fig. 4C). Meanwhile, the EC_{50} value of colchicine in the BT-16 spheroid displayed a similar effectiveness to that of doxorubicin (Fig. 4F). These findings suggest that colchicine exhibits significant efficacy in 3D AT/RT spheroid models, supporting its potential as a therapeutic agent for AT/RT treatment.

Discussion

The primary objective of this study was to repurpose a non-chemotherapeutic FDA-approved drug for anti-AT/RT activity. This study revealed that colchicine, an established anti-gout and anti-familial Mediterranean fever (FMF) drug, exhibits promising anti-AT/RT activity by inhibiting AT/RT cell proliferation. Colchicine, an anti-mitotic agent, demonstrated an IC_{50} value significantly lower than that of doxorubicin, a commonly used chemotherapeutic agent for AT/RT treatment. Colchicine, derived from *Colchicum autumnale*, exerts its anticancer activity by binding to microtubular ends and inhibiting the polymerization of microtubules, thus disrupting cell division. It is well-established that colchicine prevents mitotic progression by arresting cells in the metaphase. Colchicine's ability to attach to tubulins is one of its common modes of action in therapeutic activities.³⁵ Microtubules are composed of α - and β -tubulin heterodimers, which are important cytoskeleton components. Colchicine binds to soluble tubulin to form the tubulin-colchicine (TC) complex, which subsequently binds to microtubular ends and disturbs tubulin lattice dynamics.^{36–38} Depending on its concentration, colchicine can either promote or inhibit microtubule polymerization. At lower concentrations, colchicine specifically inhibits microtubule polymerization, ultimately leading to cell cycle arrest and reduced tumor cell viability.³⁵

In this study, BT-12 cells were found to be more sensitive to colchicine than BT-16 cells. This observation is consistent with findings for another mitotic inhibitor, paclitaxel, which has demonstrated effectiveness against both AT/RT cell lines.³³ Additionally, BT-12 cells showed significantly higher sensitivity to cisplatin than BT-16 cells,³⁴ suggesting that BT-16 cells may exhibit a desensitized response to certain drugs relative to BT-12 cells. Higher proliferative activity has also been observed in BT-12 cells, as indicated by increased Ki-67 protein expression,³⁹ a widely used marker for cell proliferation in human tumors.⁴⁰ The process of cell proliferation depends heavily on microtubule polymerization, which plays a central role in maintaining the intracellular cytoskeletal framework. The dynamic nature of microtubule polymerization is particularly crucial for numerous cellular functions, especially in tumor cells.⁴¹ These factors likely contribute to the enhanced sensitivity of BT-12 cells to anti-mitotic agents such as colchicine and paclitaxel compared to BT-16 cells.

Additionally, colchicine was evaluated for its cytotoxicity in human brain endothelial cells and normal human astrocytes, and the results showed a CC_{50} value higher than 20 μ M, which is more than two orders of magnitude higher than its IC_{50} . This indicates that colchicine is relatively safe for normal brain cells and brain endothelial cells, critical components of the blood–brain barrier, which are among the first cell types exposed to drugs prior to their penetration into the brain. By contrast, doxorubicin displayed higher cytotoxicity with a considerably narrower therapeutic window compared to colchicine. These results strongly support the further investigation of colchicine as a safer and more effective anti-AT/RT agent. Beyond traditional *in vitro* 2D cell cultures, the anticancer activity of colchicine was also assessed in 3D cancer spheroid models, which more closely mimic the *in vivo* tumor microenvironment. These spheroid models are composed of heterogeneous cell populations that exhibit varying behavior depending on their levels of exposure to oxygen and nutrients. These include proliferating cells, quiescent cells, and hypoxic cells, which alter drug responsiveness, leading to changes in IC_{50} values that differ from those in 2D culture.⁴² This study demonstrated that colchicine effectively inhibited 3D AT/RT spheroid viability at nanomolar concentrations, 14 nM for BT-12 spheroid and 37 nM for BT-16 spheroid. These findings further validate colchicine's potential as a repurposed therapeutic agent for AT/RT treatment.

Studies on the effects of colchicine on 3D AT/RT spheroids have revealed that, even at higher concentrations, colchicine fails to completely eradicate cancer cells within the spheroid. This limitation is likely due to the enhanced drug resistance of cancer cells residing in the deeper layers of the spheroid. These cells may adapt by upregulating efflux transporter proteins, which protect them from the cytotoxic effects of drugs and other harmful agents.^{43–45} To address this issue, a co-treatment strategy combining colchicine with an efflux transporter inhibitor, such as verapamil, is proposed to enhance therapeutic efficacy. Furthermore, cancer cells located in the inner regions of the spheroid often transition from a highly proliferative state to a quiescent state, reducing ATP consumption required for processes such as cell cycle progression.⁴⁶ This adaptation further limits the effectiveness of colchicine, which acts as an antimitotic agent by binding to tubulin heterodimers near the exchangeable GTP-binding site, disrupting microtubule polymerization. This destabilization ultimately induces programmed cell death, or apoptosis.⁴⁷

Colchicine is well known for its therapeutic applications in treating gout^{48–50} and familial Mediterranean fever (FMF).^{51–53} Additionally, colchicine has been used to manage other conditions such as Behcet's disease (BD),^{54–56} pericarditis,^{57–59} coronary artery disease,^{60,61} and various inflammatory and fibrotic disorders.^{62,63} When colchicine is prescribed daily and long-term for FMF, the most common side effects (affecting up to 20% of patients) include abdominal pain, diarrhea, nausea, and vomiting. These symptoms are typically mild, temporary, and resolve when the dose is reduced. When used acutely for gout flares at doses up to 1.8 mg within 2 hours, diarrhea (23%) is the most frequently reported side effect.⁴⁸ However, colchicine is



considered safe at a dosage of 1.5 mg, although it was not effective in halting disease progression or reducing mortality in patients with severe COVID-19.⁶⁴ For children under 5 years of age with FMF or other autoinflammatory diseases, a daily colchicine dose of 0.5 mg is considered safe.^{65,66} According to the 2007 guidelines, the recommended initial dosage varies by age: 0.5 mg per day for children aged under 5 years, 1.0 mg per day for those aged 5–10 years, and 1.5 mg per day for those aged over 10 years.⁶⁶ Based on this dosing approach, colchicine may be a potential alternative treatment option for pediatric patients with AT/RT.

Numerous studies have highlighted the anticancer properties of colchicine across a variety of cancers. One such study investigated the effects of colchicine on human breast adenocarcinoma MCF-7 cells, showing that it inhibited MMP-2 mRNA expression and caused cell cycle arrest at the G₂/M stage of mitosis, which led to reduced cell proliferation.⁶⁷ Colchicine's efficacy against hypopharyngeal carcinoma has also been reported. Colchicine inhibited the formation and proliferation of human hypopharyngeal carcinoma cells in a dose-dependent manner. This was achieved through the suppression of key pathways involved in cancer progression.

Colchicine downregulated MMP9, μ PA, and FAK/SRC signaling pathways, effectively reducing cell invasion, migration, and adhesion. Furthermore, colchicine induced apoptosis by activating caspase-3,⁶⁸ preventing metastasis and promoting cancer cell death. In addition to breast and hypopharyngeal carcinoma, colchicine has shown a significant anticancer effect on gastric carcinoma cells in a dose-dependent manner. Colchicine promoted apoptosis in gastric carcinoma cells through the activation of caspase-3. This was mediated *via* the suppression of the PI3K/Akt/mTOR signaling pathway.⁶⁹ Colchicine has also been studied against colorectal cancer cells, where it exhibits dose-dependent cytotoxic effects. Its administration led to an increase in ROS generation, activation of caspase-3, upregulation of pro-apoptotic protein BAX, and downregulation of the anti-apoptotic protein Bcl-2. These findings indicate that colchicine induces apoptosis, possibly *via* the intrinsic apoptotic signaling route, in colorectal cancer cells.⁷⁰ These studies collectively highlight colchicine's ability to target multiple mechanisms involved in cancer progression, including inhibition of proliferation, migration, and invasion, as well as the induction of apoptosis.




Fig. 5 Proposed antimitotic mechanism of colchicine. Colchicine disrupts microtubule stability by binding to two tubulin heterodimers near the exchangeable GTP-binding site, forming a tubulin-colchicine (TC) complex. This interaction destabilizes tubulin, preventing proper microtubule assembly and arresting mitotic cells at the G₂/M phase. As a result, AT/RT cell proliferation is inhibited, particularly in the proliferative zone of 3D AT/RT spheroids, ultimately triggering programmed cell death, often known as apoptosis.⁴⁷ The cell cycle consists of four main phases: G₁ (first growth phase), where the cell grows and carries out normal metabolic functions; S (synthesis phase), during which DNA replication occurs; G₂ (second growth phase), preparing the cell for mitosis; and M (mitotic phase), where nuclear division results in two genetically identical daughter cells. The M phase is further divided into prophase, metaphase, anaphase, and telophase. (Created by [BioRender.com](https://www.biorender.com/)/Mahidol University.)

While colchicine has been extensively studied in various cancer types, its potential as an anti-AT/RT agent remains unexplored. The evidence of its anticancer effectiveness strongly supports its capacity to act as a potential candidate for AT/RT treatment. By targeting key signaling pathways, inhibiting metastasis, and promoting apoptosis, colchicine could offer a novel therapeutic approach for AT/RTs. Furthermore, this study suggests a potential mechanism for colchicine's effect on AT/RTs. Colchicine binds to tubulin, forming a tubulin-colchicine (TC) complex, which interferes with cell cycle progression by arresting mitotic cells at the G₂/M phase. This disruption ultimately inhibits AT/RT cell proliferation, particularly within the proliferative zone of 3D AT/RT spheroids (Fig. 5). Additionally, colchicine's FDA-approved status makes it a particularly attractive candidate for drug repurposing. Unlike conventional chemotherapeutic agents, colchicine demonstrates a lower risk of adverse effects as evidenced by its selective toxicity and favourable therapeutic window in normal brain and endothelial cells.

Collectively, colchicine has the potential to be successfully repurposed as an AT/RT treatment, and combining colchicine with other drugs to overcome resistance may offer a potential strategy for improving treatment outcomes. Further investigation into the combination treatment of colchicine and other efflux transporter inhibitors and the mechanistic study of colchicine are also underway to confirm its therapeutic value. These findings will contribute to our understanding of colchicine as a possible new treatment for AT/RTs, offering a safer and potentially more effective alternative to traditional chemotherapy.

Methods

Cell culture

The human atypical teratoid/rhabdoid tumor cell lines (BT-12 and BT-16 cells) were generously provided by Peter Houghton from the St. Jude Children's Research Hospital (Memphis, TN, USA) through Professor Suradej Hongeng. BT-12 and BT-16 cells were cultured in RPMI 1640 medium, which was supplemented with 10% FBS and 1% P/S (Penicillin/Streptomycin). The human blood-brain barrier cell line (hCMEC/D3 cells) was purchased from Merck (Schuchardt, Darmstadt, Germany). hCMEC/D3 cells were cultured in EndoGRO™-MV complete medium, which was supplemented with 1 ng mL⁻¹ FGF-2. The primary human astrocytes (HA) were purchased from ScienCell™ Research Laboratories (Carlsbad, CA, USA). Astrocytes were cultured in astrocyte medium (AM), which was supplemented with astrocyte growth supplement (AGS) and 2% FBS.

FDA-approved drug library preparation

A library of 2130 FDA-approved drugs was purchased from Selleck Chemicals (Houston, TX, USA). All FDA-approved drugs were dissolved in DMSO at 10 mM concentration. For the compound screening, 2130 FDA-approved drugs were diluted in an assay medium at the final concentration of 10 μM.

High-throughput screening of 2130 FDA-approved drugs for anti-AT/RT cells in 2D traditional culture

Atypical teratoid/rhabdoid tumor cell lines were seeded into 96-well clear plates (Corning Acton, MA, USA) at a density of 2×10^3 cells per well. The cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% P/S (Penicillin/Streptomycin) and incubated at 37 °C with 5% CO₂ for 24 hours. Following this incubation period, the screening of compounds was carried out using a high-throughput liquid handling system (JANUS) (PerkinElmer, Waltham, MA, USA). For primary screening, the compounds were added into the cell plates at a final concentration of 10 μM and incubated for 72 hours under the same conditions. After 72 hours of compound treatment, the culture media containing the compounds was removed, and serum-free media containing MTT was added to each well. The cells were incubated with the MTT solution for 3 hours at 37 °C with 5% CO₂. After the 3 hours incubation period, the serum-free medium containing MTT was removed, and DMSO was added to each well and the absorbance of resulting-colored solution was measured at 570 nm by Multi-Mode Microplate Reader (ENVISION) (PerkinElmer, Waltham, MA, USA). The cell viability was quantified as a percentage of the untreated control. The compounds were selected for further investigation if they reduced cancer cell viability to 20% or less.

Secondary screening (dose-dependent manner) for IC₅₀ of anti-AT/RT cells

Atypical teratoid/rhabdoid tumor cell lines were seeded into 96-well clear plates at a density of 2×10^3 cells per well. The cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% P/S and incubated at 37 °C with 5% CO₂ for 24 hours. After 24 hours of incubation, the test compounds were added to the wells in a dose-dependent manner with the final concentrations of 20, 2, 0.2, 0.02, 0.002, and 0.0002 μM. The plates were then incubated for 72 hours at 37 °C, 5% CO₂. After the 72-hour treatment, the culture media containing the compounds was removed, and serum-free media containing MTT was added to each well. The cells were incubated for 3 hours at 37 °C with 5% CO₂. Following this incubation, the serum-free media containing MTT was removed, and DMSO was added to the wells and the absorbance of resulting-colored solution was measured at 570 nm by Multi-Mode Microplate Reader (ENVISION). The calculation of IC₅₀ was performed using GraphPad Prism 9 (GraphPad Software, Inc., San Diego, CA, USA).

High-content imaging analysis of hit compounds for anti-AT/RT cells in 3D spheroid culture

Atypical teratoid/rhabdoid tumor cell lines were seeded into 96-well ultra-low attachment clear plates (Corning (Acton, MA, USA)) at a density of 5×10^3 cells per well. The cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% P/S. The plates were incubated at 37 °C with 5% CO₂ for 72 hours to allow the formation of 3D spheroids. After this incubation period, compounds were added to the plates in



a dose-dependent manner and further incubated for an additional 72 hours at 37 °C with 5% CO₂. Following this treatment period, the 3D spheroids were stained with Hoechst (live cell staining) and ethidium homodimer (dead cell staining) at a 1 : 1000 dilution ratios of each dye reagent to the culture medium. The 3D spheroids were incubated with the dye reagents for 2 hours. The stained spheroids were then analyzed using a high-content imaging system (Operetta) (PerkinElmer (Waltham, MA, USA)). The calculation of IC₅₀ was performed using GraphPad Prism 9.

Cytotoxicity test in BBB and astrocytes

The hCMEC/D3 cells representing the BBB were seeded into 96-well clear plates at a density of 2×10^4 cells per well. The cells were cultured in EndoGRO™-MV complete medium supplemented with 1 ng mL⁻¹ FGF-2 and incubated at 37 °C with 5% CO₂ for 24 hours. Alternatively, human astrocytes were seeded into 96-well clear plates at a density of 5×10^3 cells per well and cultured in astrocyte medium (AM) supplemented with astrocyte growth supplement (AGS) and 2% FBS under the same condition. After 24 hours of incubation, selected compounds were added to the wells of both BBB and astrocytes plates in a dose-dependent manner with final concentrations of 20, 5, 1.25, 0.313, 0.078, 0.020, and 0.005 μM. The plates were then incubated for 72 hours at 37 °C with 5% CO₂. Following this period, the culture media containing the compound was removed, and serum-free media containing MTT was added to each well. The cells were incubated with the MTT solution for 3 hours under the same conditions.

After the 3-hour incubation, the solution was removed, and DMSO was added to each well and the absorbance of the resulting-colored solution was measured at 570 nm by Multi-Mode Microplate Reader (ENVISION). The calculation of CC₅₀ was performed using GraphPad Prism 9.

Statistical analysis

All data were analyzed using GraphPad Prism 9 (GraphPad Software, Inc., San Diego, CA, USA). The Z-factor is a measure of statistical effect size and an attempt to quantify the suitability of a particular assay and assess the quality of an assay for high throughput screening.

Abbreviations

AT/RT	Atypical teratoid/rhabdoid tumor
AKT	Ak strain transforming/protein kinase B (PKB)
BAX	Bcl2 associated X-protein
Bcl2	B-cell lymphoma 2
CNS	Central nervous system
FAK/SRC	Focal adhesion kinase/sarcoma non-receptor tyrosine kinase
FDA	Food and Drug Administration
GTP	Guanosine triphosphate
hCMEC/	Human cerebral microvascular endothelial cell/
D3	clone D3

HIV	Human immunodeficiency virus
MMP-2	Matrix metalloproteinase-2
MMP-9	Matrix metalloproteinase-9
mTOR	Mammalian target of rapamycin
PI3K	Phosphoinositide 3-kinases
ROS	Reactive oxygen species
SMARCB1	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1
VEGFR2	Vascular endothelial growth factor 2

Data availability

The data supporting the findings of this article have been included as part of the ESI.†

Author contributions

P. K., K. J., and S. S. conducted the experiments and analyzed the data; P. K., S. B., P. W., S. H. and S. C. conceptualized the idea; S. B., P. W., S. H. and S. C. provided materials and resources; S. B., S. H. and S. C. provided funding; S. C. supervised all research; and P. K. and S. C. wrote, reviewed, and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This research was partially supported by the Ramathibodi Foundation and Thailand Center of Excellence for Life Sciences (TCELS), and also by the Faculty of Science, Mahidol University via the Reinventing University Project. The authors would like to thank Dr Witchuda Saengsawang, Dr Jiraporn Panmanee and Dr Sujira Mukda for discussions.

References

- 1 M. Bhattacharjee, J. Hicks, L. Langford, R. Dauser, D. Strother, M. Chintagumpala, M. Horowitz, L. Cooley and H. Vogel, *Ultrastruct. Pathol.*, 1997, **21**, 369–378.
- 2 N. Gökden, O. Nappi, P. E. Swanson, J. D. Pfeifer, R. T. Vollmer, M. R. Wick and P. A. Humphrey, *Am. J. Surg. Pathol.*, 2000, **24**, 1329–1338.
- 3 I. Versteeg, N. Sévenet, J. Lange, M.-F. Rousseau-Merck, P. Ambros, R. Handgretinger, A. Aurias and O. Delattre, *Nature*, 1998, **394**, 203–206.
- 4 D. N. Louis, A. Perry, G. Reifenberger, A. von Deimling, D. Figarella-Branger, W. K. Cavenee, H. Ohgaki, O. D. Wiestler, P. Kleihues and D. W. Ellison, *Acta Neuropathol.*, 2016, **131**, 803–820.
- 5 Y. S. Dho, S. K. Kim, J. E. Cheon, S. H. Park, K. C. Wang, J. Y. Lee and J. H. Phi, *Childs Nerv. Syst.*, 2015, **31**, 1305–1311.



- 6 T. Tamiya, H. Nakashima, Y. Ono, S. Kawada, S. Hamazaki, T. Furuta, K. Matsumoto and T. Ohmoto, *Pediatr. Neurosurg.*, 2000, **32**, 145–149.
- 7 Q. T. Ostrom, Y. Chen, P. M. de Blank, A. Ondracek, P. Farah, H. Gittleman, Y. Wolinsky, C. Kruchko, M. L. Cohen, D. J. Brat and J. S. Barnholtz-Sloan, *Neuro-Oncology*, 2014, **16**, 1392–1399.
- 8 A. T. Reddy, D. R. Strother, A. R. Judkins, P. C. Burger, I. F. Pollack, M. D. Krailo, A. B. Buxton, C. Williams-Hughes, M. Fouladi, A. Mahajan, T. E. Merchant, B. Ho, C. M. Mazewski, V. A. Lewis, A. Gajjar, L. G. Vezina, T. N. Booth, K. W. Parsons, V. L. Poss, T. Zhou, J. A. Biegel and A. Huang, *J. Clin. Oncol.*, 2020, **38**, 1175–1185.
- 9 L. Lafay-Cousin, T. Fay-McClymont, D. Johnston, C. Fryer, K. Scheinemann, A. Fleming, J. Hukin, L. Janzen, S. Guger, D. Strother, D. Mabbott, A. Huang and E. Bouffet, *Pediatr. Blood Cancer*, 2015, **62**, 1265–1269.
- 10 M. C. Frühwald, J. A. Biegel, F. Bourdeaut, C. W. Roberts and S. N. Chi, *Neuro-Oncology*, 2016, **18**, 764–778.
- 11 M. Park, J. W. Han, S. M. Hahn, J. A. Lee, J. Y. Kim, S. H. Shin, D. S. Kim, H. I. Yoon, K. T. Hong, J. Y. Choi, H. J. Kang, H. Y. Shin, J. H. Phi, S. K. Kim, J. W. Lee, K. H. Yoo, K. W. Sung, H. H. Koo, D. H. Lim, H. J. Shin, H. Kim, K. N. Koh, H. J. Im, S. D. Ahn, Y. S. Ra, H. J. Baek, H. Kook, T. Y. Jung, H. S. Choi, C. Y. Kim, H. J. Park and C. J. Lyu, *Cancer Res. Treat.*, 2021, **53**, 378–388.
- 12 J. M. Hilden, S. Meerbaum, P. Burger, J. Finlay, A. Janss, B. W. Scheithauer, A. W. Walter, L. B. Rorke and J. A. Biegel, *J. Clin. Oncol.*, 2004, **22**, 2877–2884.
- 13 J. S. Shim and J. O. Liu, *Int. J. Biol. Sci.*, 2014, **10**, 654–663.
- 14 N. Nosengo, *Nature*, 2016, **534**, 314–316.
- 15 C. M. Rudin, J. R. Brahmer, R. A. Jurgens, C. L. Hann, D. S. Ettinger, R. Sebree, R. Smith, B. T. Aftab, P. Huang and J. O. Liu, *J. Thorac. Oncol.*, 2013, **8**, 619–623.
- 16 E. S. Antonarakis, E. I. Heath, D. C. Smith, D. Rathkopf, A. L. Blackford, D. C. Danila, S. King, A. Frost, A. S. Ajiboye, M. Zhao, J. Mendonca, S. K. Kachhap, M. A. Rudek and M. A. Carducci, *Oncologist*, 2013, **18**, 163–173.
- 17 J. Xu, Y. Dang, Y. R. Ren and J. O. Liu, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 4764–4769.
- 18 B. A. Nacev, P. Grassi, A. Dell, S. M. Haslam and J. O. Liu, *J. Biol. Chem.*, 2011, **286**, 44045–44056.
- 19 T. B. Brunner, M. Geiger, G. G. Grabenbauer, M. Lang-Welzenbach, T. S. Manton, A. Cavallaro, R. Sauer, W. Hohenberger and W. G. McKenna, *J. Clin. Oncol.*, 2008, **26**, 2699–2706.
- 20 E. C. Costa, V. M. Gaspar, P. Coutinho and I. J. Correia, *Biotechnol. Bioeng.*, 2014, **111**, 1672–1685.
- 21 K. Ludwig, E. S. Tse and J. Y. Wang, *BMC Cancer*, 2013, **13**, 221.
- 22 A. Amann, M. Zwierzina, G. Gamerith, M. Bitsche, J. M. Huber, G. F. Vogel, M. Blumer, S. Koeck, E. J. Pechriggl, J. M. Kelm, W. Hilbe and H. Zwierzina, *PLoS One*, 2014, **9**, e92511.
- 23 I. Dufau, C. Frongia, F. Sicard, L. Dedieu, P. Cordelier, F. Ausseil, B. Ducommun and A. Valette, *BMC Cancer*, 2012, **12**, 15.
- 24 S. Shankar, D. Nall, S. N. Tang, D. Meeker, J. Passarini, J. Sharma and R. K. Srivastava, *PLoS One*, 2011, **6**, e16530.
- 25 A. Takagi, M. Watanabe, Y. Ishii, J. Morita, Y. Hirokawa, T. Matsuzaki and T. Shiraishi, *Anticancer Res.*, 2007, **27**, 45–53.
- 26 M. Wartenberg, S. Gronczynska, M. M. Bekhite, T. Saric, W. Niedermeier, J. Hescheler and H. Sauer, *Int. J. Cancer*, 2005, **113**, 229–240.
- 27 M. Wartenberg, E. Hoffmann, H. Schwindt, F. Grünheck, J. Petros, J. R. Arnold, J. Hescheler and H. Sauer, *FEBS Lett.*, 2005, **579**, 4541–4549.
- 28 E. C. Costa, A. F. Moreira, D. de Melo-Diogo, V. M. Gaspar, M. P. Carvalho and I. J. Correia, *Biotechnol. Adv.*, 2016, **34**, 1427–1441.
- 29 A. McIntyre, S. Patiar, S. Wigfield, J. L. Li, I. Ledaki, H. Turley, R. Leek, C. Snell, K. Gatter, W. S. Sly, R. D. Vaughan-Jones, P. Swietach and A. L. Harris, *Clin. Cancer Res.*, 2012, **18**, 3100–3111.
- 30 M. P. Valley, K. R. Kupcho, C. A. Zimprich, A. L. Niles, J. J. Cali, J. M. Kelm, W. Moritz and D. F. Lazar, *Cancer Res.*, 2014, **74**, 3731.
- 31 I. Ayvaz, D. Sunay, E. Sariyar, E. Erdal and Z. F. Karagonlar, *J. Gastrointest. Cancer*, 2021, **52**, 1294–1308.
- 32 I. Alimova, D. K. Birks, P. S. Harris, J. A. Knipstein, S. Venkataraman, V. E. Marquez, N. K. Foreman and R. Vibhakkar, *Neuro-Oncology*, 2013, **15**, 149–160.
- 33 A. Morin, C. Soane, A. Pierce, B. Sanford, K. L. Jones, M. Crespo, S. Zahedi, R. Vibhakkar and J. M. Mulcahy Levy, *Neuro-Oncology Adv.*, 2020, **2**, vdaa051.
- 34 P. Hannon Barroeta, S. Magnano, M. J. O'Sullivan and D. M. Zisterer, *Cancer Treat. Res. Commun.*, 2022, **32**, 100584.
- 35 Y. Y. Leung, L. L. Yao Hui and V. B. Kraus, *Semin. Arthritis Rheum.*, 2015, **45**, 341–350.
- 36 M. A. Jordan, *Curr. Med. Chem.: Anti-Cancer Agents*, 2002, **2**, 1–17.
- 37 B. Karahalil, S. Yardım-Akaydin and S. Nacak Baytas, *Arh. Hig. Rada Toksikol.*, 2019, **70**, 160–172.
- 38 Z. Cheng, X. Lu and B. Feng, *Transl. Cancer Res.*, 2020, **9**, 4020–4027.
- 39 J. Casaos, S. Huq, T. Lott, R. Felder, J. Choi, N. Gorelick, M. Peters, Y. Xia, R. Maxwell, T. Zhao, C. Ji, T. Simon, J. Sesen, S. J. Scotland, R. E. Kast, J. Rubens, E. Raabe, C. G. Eberhart, E. M. Jackson, H. Brem, B. Tyler and N. Skuli, *Oncotarget*, 2018, **9**, 8054–8067.
- 40 S. Uxa, P. Castillo-Binder, R. Kohler, K. Stangner, G. A. Müller and K. Engeland, *Cell Death Differ.*, 2021, **28**, 3357–3370.
- 41 F. Mollinedo and C. Gajate, *Apoptosis*, 2003, **8**, 413–450.
- 42 M. Kapałczyńska, T. Kolenda, W. Przybyła, M. Zajączkowska, A. Teresiak, V. Filas, M. Ibbs, R. Bliźniak, Ł. Łuczewski and K. Lamperska, *Arch. Med. Sci.*, 2018, **14**, 910–919.
- 43 A. Filipiak-Duliban, K. Brodaczewska, A. Kajdasz and C. Kieda, *Int. J. Mol. Sci.*, 2022, **23**, 1166.



- 44 M. Świerczewska, K. Sterzyńska, M. Ruciński, M. Andrzejewska, M. Nowicki and R. Januchowski, *Biomed. Pharmacother.*, 2023, **165**, 115152.
- 45 T. M. Achilli, S. McCalla, J. Meyer, A. Tripathi and J. R. Morgan, *Mol. Pharm.*, 2014, **11**, 2071–2081.
- 46 M. Zanoni, F. Piccinini, C. Arienti, A. Zamagni, S. Santi, R. Polico, A. Bevilacqua and A. Tesei, *Sci. Rep.*, 2016, **6**, 19103.
- 47 P. Dhyani, C. Quispe, E. Sharma, A. Bahukhandi, P. Sati, D. C. Attri, A. Szopa, J. Sharifi-Rad, A. O. Docea, I. Mardare, D. Calina and W. C. Cho, *Cancer Cell Int.*, 2022, **22**, 206.
- 48 R. A. Terkeltaub, D. E. Furst, K. Bennett, K. A. Kook, R. S. Crockett and M. W. Davis, *Arthritis Rheum.*, 2010, **62**, 1060–1068.
- 49 M. Hamburger, H. S. Baraf, T. C. Adamson III, J. Basile, L. Bass, B. Cole, P. P. Doghramji, G. A. Guadagnoli, F. Hamburger, R. Harford, J. A. Lieberman III, D. R. Mandel, D. A. Mandelbrot, B. P. McClain, E. Mizuno, A. H. Morton, D. B. Mount, R. S. Pope, K. G. Rosenthal, K. Setoodeh, J. L. Skosey and N. L. Edwards, *Postgrad. Med.*, 2011, **123**, 3–36.
- 50 D. Khanna, P. P. Khanna, J. D. Fitzgerald, M. K. Singh, S. Bae, T. Neogi, M. H. Pillinger, J. Merrill, S. Lee, S. Prakash, M. Kaldas, M. Gogia, F. Perez-Ruiz, W. Taylor, F. Lioté, H. Choi, J. A. Singh, N. Dalbeth, S. Kaplan, V. Niyyar, D. Jones, S. A. Yarows, B. Roessler, G. Kerr, C. King, G. Levy, D. E. Furst, N. L. Edwards, B. Mandell, H. R. Schumacher, M. Robbins, N. Wenger and R. Terkeltaub, *Arthritis Care Res.*, 2012, **64**, 1447–1461.
- 51 C. A. Dinarello, S. M. Wolff, S. E. Goldfinger, D. C. Dale and D. W. Alling, *N. Engl. J. Med.*, 1974, **291**, 934–937.
- 52 E. Ben-Chetrit, *J. Nephrol.*, 2003, **16**, 431–434.
- 53 T. Kallinich, D. Haffner, T. Niehues, K. Huss, E. Lainka, U. Neudorf, C. Schaefer, S. Stojanov, C. Timmann, R. Keitzer, H. Ozdogan and S. Ozen, *Pediatrics*, 2007, **119**, e474–e483.
- 54 M. Takeuchi, Y. Asukata, T. Kawagoe, N. Ito, T. Nishide and N. Mizuki, *Ocul. Immunol. Inflammation*, 2012, **20**, 193–197.
- 55 F. Davatchi, B. Sadeghi Abdollahi, A. Tehrani Banihashemi, F. Shahram, A. Nadji, H. Shams and C. Chams-Davatchi, *Mod. Rheumatol.*, 2009, **19**, 542–549.
- 56 A. Sun, Y. P. Wang, J. S. Chia, B. Y. Liu and C. P. Chiang, *J. Oral Pathol. Med.*, 2009, **38**, 401–405.
- 57 M. Imazio, A. Brucato, R. Cemin, S. Ferrua, R. Belli, S. Maestroni, R. Trincherro, D. H. Spodick and Y. Adler, *Ann. Intern. Med.*, 2011, **155**, 409–414.
- 58 M. Imazio, R. Belli, A. Brucato, R. Cemin, S. Ferrua, F. Beqaraj, D. Demarie, S. Ferro, D. Forno, S. Maestroni, D. Cumetti, F. Varbella, R. Trincherro, D. H. Spodick and Y. Adler, *Lancet*, 2014, **383**, 2232–2237.
- 59 M. Imazio, A. Brucato, R. Cemin, S. Ferrua, S. Maggiolini, F. Beqaraj, D. Demarie, D. Forno, S. Ferro, S. Maestroni, R. Belli, R. Trincherro, D. H. Spodick and Y. Adler, *N. Engl. J. Med.*, 2013, **369**, 1522–1528.
- 60 S. M. Nidorf, J. W. Eikelboom, C. A. Budgeon and P. L. Thompson, *J. Am. Coll. Cardiol.*, 2013, **61**, 404–410.
- 61 S. Devereux, G. Giannopoulos, K. Raisakis, C. Kossyvakis, A. Kaoukis, V. Panagopoulou, M. Driva, G. Hahalis, V. Pyrgakis, D. Alexopoulos, A. S. Manolis, C. Stefanadis and M. W. Cleman, *J. Am. Coll. Cardiol.*, 2013, **61**, 1679–1685.
- 62 V. Fontes, L. Machet, B. Huttenberger, G. Lorette and L. Vaillant, *Ann. Dermatol. Venereol.*, 2002, **129**, 1365–1369.
- 63 E. Fiorucci, G. Lucantoni, G. Paone, M. Zotti, B. E. Li, M. Serpilli, P. Regimenti, I. Cammarella, G. Puglisi and G. Schmid, *Eur. Rev. Med. Pharmacol. Sci.*, 2008, **12**, 105–111.
- 64 A. Absalón-Aguilar, M. Rull-Gabayet, A. Pérez-Fragoso, N. R. Mejía-Domínguez, C. Núñez-Álvarez, D. Kershenobich-Stalnikowitz, J. Sifuentes-Osornio, A. Ponce-de-León, F. González-Lara, E. Martín-Nares, S. Montesinos-Ramírez, M. Ramírez-Alemón, P. Ramírez-Rangel, M. F. Márquez, J. C. Plata-Corona, G. Juárez-Vega, D. Gómez-Martín and J. Torres-Ruiz, *J. Gen. Intern. Med.*, 2022, **37**, 4–14.
- 65 T. Welzel, A. L. Wildermuth, N. Deschner, S. M. Benseler and J. B. Kuemmerle-Deschner, *Pediatr. Rheumatol.*, 2021, **19**, 142.
- 66 A. M. Knieper, J. Klotzsche, D. Föll, H. Wittkowski, E. Lainka and T. Kallinich, *Pediatr. Rheumatol.*, 2015, **13**, O44.
- 67 F. Bakar Ateş, N. Özmen, E. Kaya Sezginer and E. E. Kurt, *Türk Hij. Deneyisel Biyol. Derg.*, 2018, **75**, 239–244.
- 68 J. H. Cho, Y. H. Joo, E. Y. Shin, E. J. Park and M. S. Kim, *Anticancer Res.*, 2017, **37**, 6269–6280.
- 69 T. Zhang, W. Chen, X. Jiang, L. Liu, K. Wei, H. Du, H. Wang and J. Li, *Biosci. Rep.*, 2019, **39**, BSR20181802.
- 70 Z. Huang, Y. Xu and W. Peng, *Mol. Med. Rep.*, 2015, **12**, 5939–5944.

